These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8070030)

  • 1. Pharmacodynamics and long-term toxicity of etoposide.
    Kobayashi K; Ratain MJ
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S64-8. PubMed ID: 8070030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New perspectives on the toxicity of etoposide.
    Kobayashi K; Ratain MJ
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):78-83. PubMed ID: 1492230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks.
    Smith MA; Rubinstein L; Ungerleider RS
    Med Pediatr Oncol; 1994; 23(2):86-98. PubMed ID: 8202047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia.
    Felix CA; Winick NJ; Negrini M; Bowman WP; Croce CM; Lange BJ
    Cancer Res; 1993 Jul; 53(13):2954-6. PubMed ID: 8319201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia.
    Relling MV; Yanishevski Y; Nemec J; Evans WE; Boyett JM; Behm FG; Pui CH
    Leukemia; 1998 Mar; 12(3):346-52. PubMed ID: 9529129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etoposide and teniposide in the treatment of acute leukemia.
    Björkholm M
    Med Oncol Tumor Pharmacother; 1990; 7(1):3-10. PubMed ID: 2187120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide: current status and future perspectives in the management of malignant neoplasms.
    Belani CP; Doyle LA; Aisner J
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S118-26. PubMed ID: 8070020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.
    Chard RL; Krivit W; Bleyer WA; Hammond D
    Cancer Treat Rep; 1979; 63(11-12):1755-9. PubMed ID: 294306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.
    Pui CH; Ribeiro RC; Hancock ML; Rivera GK; Evans WE; Raimondi SC; Head DR; Behm FG; Mahmoud MH; Sandlund JT
    N Engl J Med; 1991 Dec; 325(24):1682-7. PubMed ID: 1944468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epipodophyllotoxins in the treatment of childhood cancer.
    Rivera GK; Pui CH; Santana VM; Pratt CB; Crist WM
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S89-95. PubMed ID: 8070034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary acute myeloblastic leukemia in a child with acute lymphoblastic leukemia treated with epipodophyllotoxins.
    Ozbek N; Cetin M; Tuncer AM; Yetgin S
    Turk J Pediatr; 1995; 37(3):279-82. PubMed ID: 7502369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
    Van Echo DA; Wiernik PH; Aisner J
    Cancer Clin Trials; 1980; 3(4):325-8. PubMed ID: 6933027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of secondary leukemia in anaplastic seminoma patient treated with long-term chemotherapy].
    Kamai T; Touma T; Masuda H; Hyouchi N; Okuno T; Yonese J; Fukuda H; Tachibana Y; Ishiwata D
    Nihon Hinyokika Gakkai Zasshi; 1996 May; 87(5):875-9. PubMed ID: 8691713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.
    Edick MJ; Gajjar A; Mahmoud HH; van de Poll ME; Harrison PL; Panetta JC; Rivera GK; Ribeiro RC; Sandlund JT; Boyett JM; Pui CH; Relling MV
    J Clin Oncol; 2003 Apr; 21(7):1340-6. PubMed ID: 12663724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher in vivo protein binding of etoposide in children compared with adult cancer patients.
    Liliemark E; Söderhäll S; Sirzea F; Gruber A; Osby E; Björkholm M; Zhou R; Peterson C; Liliemark J
    Cancer Lett; 1996 Aug; 106(1):97-100. PubMed ID: 8827052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide in leukemia, lymphoma and bone marrow transplantation.
    Stadtmauer EA; Cassileth PA; Gale RP
    Leuk Res; 1989; 13(8):639-50. PubMed ID: 2677526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
    Lowis SP; Pearson AD; Newell DR; Cole M
    Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoposide dosage and pharmacodynamics.
    Joel SP; Shah R; Slevin ML
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S69-75. PubMed ID: 8070031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide (VP-16-213).
    Issell BF; Crooke ST
    Cancer Treat Rev; 1979 Jun; 6(2):107-24. PubMed ID: 385138
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations.
    Stewart CF
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S76-83. PubMed ID: 8070032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.